anti-HER2-vc0101 ADC PF-06804103

{
  "id": "MLC-T-ONC-010773",
  "term": "anti-HER2-vc0101 ADC PF-06804103",
  "field": "Oncology and biomedicine",
  "definition": "A proprietary antibody-drug conjugate (ADC) composed of a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) site-specifically linked, via a protease cleavable linker, to an analog of dolastatin 10, Auristatin-0101, with potential antineoplastic activity. Upon administration, anti-HER2-vc0101 ADC PF-06804103 targets HER2 expressed on tumor cells. Upon binding, internalization and cleavage, Auristatin-0101 binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and apoptosis of HER2-expressing tumor cells. HER2, a tumor-associated antigen (TAA), is overexpressed on a variety of cancer cells.",
  "synonyms": [
    "anti-NG-HER2 ADC PF-06804103",
    "anti-NG-Her2-vc0101 ADC PF-06804103",
    "anti-HER2-vcAur0101 ADC PF-06804103",
    "antibody-drug conjugate PF-06804103"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anti-her2-vc0101-adc-pf-06804103/"
}